{"id":3677,"date":"2025-01-14T13:43:58","date_gmt":"2025-01-14T13:43:58","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=3677"},"modified":"2025-05-06T07:22:54","modified_gmt":"2025-05-06T07:22:54","slug":"daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","title":{"rendered":"\u7b2c\u4e00\u4e09\u5171\u3001Glycotope\u793e\u304b\u3089\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>Daiichi Sankyo Company, Ltd&nbsp; announced&nbsp; that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody, gatipotuzumab. Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an antibody drug conjugate (ADC) from Glycotope.<\/p><p>\u6297TA-MUC1\u306f\u3001\u7b2c\u4e00\u4e09\u5171\u304c\u958b\u767a\u4e2d\u306eADC\u3067\u3042\u308bDS-3939\u306b\u542b\u307e\u308c\u308b\u6297\u4f53\u3067\u3059\u3002DS-3939\u306f\u3001\u7b2c\u4e00\u4e09\u5171\u304c\u958b\u767a\u4e2d\u306eADC\u3067\u3042\u308bDS-3939\u306b\u542b\u307e\u308c\u308b\u6297TA-MUC1\u6297\u4f53\u3067\u3059\u3002 <a href=\"https:\/\/www.daiichisankyo.com\/\" data-no-translation=\"\">Daiichi Sankyo<\/a>&rsquo;s proprietary DXd ADC technology. DS-3939 is currently being evaluated in a phase 1\/2 clinical trial in patients with several types of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract and pancreatic cancer.<\/p><p>TA-MUC1\u306f\u816b\u760d\u7279\u7570\u7684\u306a\u819c\u8cab\u901a\u578b\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3001\u3044\u304f\u3064\u304b\u306e\u30b7\u30a2\u30eb\u9178\u8ee2\u79fb\u9175\u7d20\u306e\u767a\u73fe\u30d1\u30bf\u30fc\u30f3\u306e\u5909\u5316\u306b\u3088\u308a\u7cd6\u9396\u4ed8\u52a0\u7570\u5e38\u304c\u898b\u3089\u308c\u307e\u3059\u3002<sup>1<\/sup>&nbsp;TA-MUC1\u306f\u307b\u3068\u3093\u3069\u306e\u30d2\u30c8\u4e0a\u76ae\u764c\u3067\u904e\u5270\u767a\u73fe\u3057\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001\u764c\u6cbb\u7642\u306e\u9b45\u529b\u7684\u306a\u6a19\u7684\u3067\u3059\u3002<sup>2<\/sup>&nbsp;\u73fe\u5728\u3001TA-MUC1\u6307\u5411\u6027\u306e\u6cbb\u7642\u6cd5\u306f\u3001\u3044\u304b\u306a\u308b\u7a2e\u985e\u306e\u764c\u306b\u5bfe\u3057\u3066\u3082\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p><p>DS-3939 is an investigational potential first-in-class TA-MUC1 directed ADC. Designed using Daiichi Sankyo&rsquo;s proprietary DXd ADC technology, DS-3939 is comprised of a humanized anti-TA-MUC1 antibody, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.<\/p><p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250113621008\/en\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH\" data-no-translation=\"\">Businesswire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo Company, Ltd&nbsp; announced&nbsp; that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody, gatipotuzumab. Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an antibody drug conjugate (ADC) from Glycotope.The anti-TA-MUC1 is the antibody contained in DS-3939, an ADC being developed by Daiichi Sankyo. DS-3939 is a specifically engineered potential first-in-class TA-MUC1 directed medicine designed using Daiichi Sankyo&rsquo;s proprietary DXd ADC technology. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":4141,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[181,89],"tags":[152,151,150,149,105,106],"ppma_author":[205],"class_list":["post-3677","post","type-post","status-publish","format-standard","has-post-thumbnail","category-biotech","category-health-tech","tag-antibody","tag-antibody-drug-conjugate","tag-biotech","tag-daiichi-sankyo","tag-itbusinesstoday","tag-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T13:43:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u7b2c\u4e00\u4e09\u5171\u3001\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97","description":"\u7b2c\u4e00\u4e09\u5171\u3001TA-MUC1\u6297\u4f53gatipotuzumab\u306b\u3064\u3044\u3066Glycotope\u793e\u306b$1\u51043,250\u4e07\u30c9\u30eb\u3092\u652f\u6255\u3044\u3001\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u30ed\u30a4\u30e4\u30ea\u30c6\u30a3\u3092\u5c65\u884c","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","og_locale":"ja_JP","og_type":"article","og_title":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP","og_description":"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","og_site_name":"itbusinesstoday","article_published_time":"2025-01-14T13:43:58+00:00","article_modified_time":"2025-05-06T07:22:54+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP from Glycotope","datePublished":"2025-01-14T13:43:58+00:00","dateModified":"2025-05-06T07:22:54+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"},"wordCount":244,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","keywords":["antibody","antibody drug conjugate","Biotech","Daiichi Sankyo","itbusinesstoday","News"],"articleSection":["Biotech","Health Tech"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","name":"\u7b2c\u4e00\u4e09\u5171\u3001\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","datePublished":"2025-01-14T13:43:58+00:00","dateModified":"2025-05-06T07:22:54+00:00","description":"\u7b2c\u4e00\u4e09\u5171\u3001TA-MUC1\u6297\u4f53gatipotuzumab\u306b\u3064\u3044\u3066Glycotope\u793e\u306b$1\u51043,250\u4e07\u30c9\u30eb\u3092\u652f\u6255\u3044\u3001\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u30ed\u30a4\u30e4\u30ea\u30c6\u30a3\u3092\u5c65\u884c","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","width":1200,"height":800,"caption":"Daiichi Sankyo"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP from Glycotope"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=3677"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677\/revisions"}],"predecessor-version":[{"id":3687,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677\/revisions\/3687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/4141"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=3677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=3677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=3677"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=3677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}